What is he best known for?
The fields of study he is best known for:
- Retina
- Internal medicine
- Visual acuity
Michael Kalloniatis mainly focuses on Retina, Glutamate receptor, Biochemistry, Cell biology and Neuroscience.
In general Retina, his work in Amacrine cell is often linked to Retinopathy of prematurity linking many areas of study.
The various areas that Michael Kalloniatis examines in his Glutamate receptor study include Amino acid, NMDA receptor and Neurotransmitter.
In the field of Biochemistry, his study on Glutamine, Glycine, Agmatine and Ganglion cell layer overlaps with subjects such as Cellular localization.
His work in Cell biology is not limited to one particular discipline; it also encompasses Glutamic acid.
He has included themes like Neurochemical and Visual phototransduction in his Retinal degeneration study.
His most cited work include:
- Patterns of glutamate immunoreactivity in the goldfish retina. (257 citations)
- Separate Progenitors for Radial and Tangential Cell Dispersion during Development of the Cerebral Neocortex (221 citations)
- Amino Acid Signatures in the Primate Retina (153 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Retina, Ophthalmology, Retinal, Glutamate receptor and Glaucoma.
His biological study deals with issues like Cell biology, which deal with fields such as Kainic acid.
Michael Kalloniatis has researched Glutamate receptor in several fields, including Amino acid, gamma-Aminobutyric acid and NMDA receptor.
His research integrates issues of Optometry, Visual field, Intraocular pressure and Audiology in his study of Glaucoma.
His work carried out in the field of Neuroscience brings together such families of science as AMPA receptor and Ionotropic effect.
His Glutamine research is multidisciplinary, incorporating elements of Endocrinology and Internal medicine.
He most often published in these fields:
- Retina (30.92%)
- Ophthalmology (17.63%)
- Retinal (17.92%)
What were the highlights of his more recent work (between 2016-2021)?
- Glaucoma (15.32%)
- Ophthalmology (17.63%)
- Optical coherence tomography (8.96%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Glaucoma, Ophthalmology, Optical coherence tomography, Visual field and Retinal.
His biological study spans a wide range of topics, including Optometry, Intraocular pressure, Collaborative Care and Audiology.
His Ophthalmology research is multidisciplinary, incorporating perspectives in Tomography and Age related.
His Visual field research includes themes of Stimulus and Summation.
Retinal is closely attributed to Retina in his work.
Retina is a subfield of Neuroscience that Michael Kalloniatis investigates.
Between 2016 and 2021, his most popular works were:
- A Deep Learning-Based Algorithm Identifies Glaucomatous Discs Using Monoscopic Fundus Photographs. (37 citations)
- The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives (33 citations)
- Rod-cone crossover connectome of mammalian bipolar cells. (24 citations)
In his most recent research, the most cited papers focused on:
- Retina
- Internal medicine
- Visual acuity
Glaucoma, Visual field, Optical coherence tomography, Ophthalmology and Macular degeneration are his primary areas of study.
His Glaucoma research is multidisciplinary, incorporating elements of Family medicine, Collaborative Care, Audiology and Public hospital.
His work deals with themes such as Stimulus, Summation and Contrast, which intersect with Visual field.
Ophthalmology and Retina are commonly linked in his work.
His work carried out in the field of Retina brings together such families of science as GABAergic, Age related and Crossover.
His Macular degeneration research is multidisciplinary, relying on both Retinal pigment epithelium, Retinal and Optical coherence tomography angiography.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
